Header
Header
Article

Tibsovo Offers Oral Option for IDH1-Positive Relapsed/Refractory AML

The FDA has approved ivosidenib (Tibsovo, Agios) for the treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with an isocitrate dehydrogenase-1 (IDH1) mutation, as detected by the concurrently approved Abbott RealTime IDH1 diagnostic test.

Source link

Back to top button